| 货号 | 2022/50 |
| 别名 | (4-Chlorophenyl)(dimethoxyphosphiny |
| 供应商 | Tocris |
| 生物活性 | Selective PPARγ antagonist; antidiabetic and antiobesity agent. Attenuates troglitazone-induced PPARγ transcriptional activity (IC50 = 140 μM) without affecting ligand-stimulated PPARα, PPARβ or FXR transcriptional activity. Inhibits PPARγ-dependent adipocyte differentiation and growth in vitroandin vivo. Improves insulin sensitivity in diabetic ob/ob mice and increases HDL levels in rats in vivo. |
| 运输条件 | Blue Ice |
| 存放说明 | Ambient |
| 纯度 | >99 % |
| 计算分子量 | 358.65 |
| 分子式 | C11H17ClO7P2 |
| 可溶性/溶解性 | Soluble to 100 mM in water |
| CAS号 | 76541-72-5 |
| 参考文献 | Doggrell (2003) Do peroxisome proliferation receptor-γ antagonists have clinical potential as combined antiobesity and antidiabetic drugs? Expert.Opin.Invest.Drugs 12713. Rieussetet al (2002) A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity. Mol.Endocrinol. 16 2628. PMID: 12403851. Nguyenet al(1987)gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity. J.Med.Chem. 30 1426. PMID: 3612689. |